Payment overview · 2025
General Payments
$3,416.35
100 reported records · 15 companies
Healthcare provider profile · identity verified
David H Lau, M.D., PHD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · NEW YORK, NY · NPI 1902064421
Verified facts
What the public records show
CMS Open Payments records show David H Lau, M.D., PHD received $3,416.35 in general payments during 2025 across 100 reported records.
Boston Scientific Corporation accounted for 33.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis, Farxiga, Jardiance, Licart, Nurtec Odt, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 437 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 2444 claims for Eliquis by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Licart by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 1960 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 2444 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,135.03 | 33.2% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $448.14 | 13.1% | 21 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $361.54 | 10.6% | 22 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $243.26 | 7.1% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $204.87 | 6.0% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $194.01 | 5.7% | 7 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $188.18 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $163.58 | 4.8% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $140.90 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $121.78 | 3.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.77 | 2.0% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $65.01 | 1.9% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $32.95 | 1.0% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.98 | 0.7% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $22.35 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,416.35 | 100 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $768.92 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $448.14 | 21 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $257.41 | 16 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $243.26 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $243.10 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $204.87 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $194.01 | 7 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $188.18 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $188.18 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $159.64 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $140.90 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $121.78 | 5 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $121.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $115.26 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.77 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $65.01 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $39.22 | 1 | 2025 |
Source payment records
|
|||||
| Venclose Maven Catheter Normalized: venclose maven catheter |
Device | Bard Peripheral Vascular, Inc. | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $21.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 2444 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 437 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
130 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
437 | 83 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2444 | 412 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
98 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
1960 | 294 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
2444 | 412 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 4659 | 880 |
| Vascepa | Icosapent Ethyl | 4572 | 775 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2822 | 572 |
| Xarelto | Rivaroxaban | 2571 | 419 |
| Eliquis | Apixaban | 2444 | 412 |
| Nitroglycerin | Nitroglycerin | 2410 | 538 |
| Entresto | Sacubitril/Valsartan | 1960 | 294 |
| Ranolazine Er | Ranolazine | 1827 | 284 |
| Losartan Potassium | Losartan Potassium | 1472 | 314 |
| Clopidogrel | Clopidogrel Bisulfate | 1311 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 1272 | 271 |
| Diclofenac Epolamine | Diclofenac Epolamine | 1086 | 163 |
| Furosemide | Furosemide | 852 | 219 |
| Montelukast Sodium | Montelukast Sodium | 782 | 119 |
| Atenolol | Atenolol | 637 | 114 |
| Diclofenac Sodium | Diclofenac Sodium | 617 | 166 |
| Gabapentin | Gabapentin | 614 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 597 | 141 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 550 | 151 |
| Carvedilol | Carvedilol | 549 | 104 |
| Omeprazole | Omeprazole | 498 | 96 |
| Jardiance | Empagliflozin | 437 | 83 |
| Meclizine Hcl | Meclizine Hcl | 428 | 129 |
| Nebivolol Hcl | Nebivolol Hcl | 414 | 72 |
| Simvastatin | Simvastatin | 402 | 88 |
| Ammonium Lactate | Ammonium Lactate | 380 | 82 |
| Celecoxib | Celecoxib | 360 | 112 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 359 | 56 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 350 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 67 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 324 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 323 | 55 |
| Warfarin Sodium | Warfarin Sodium | 323 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 294 | 74 |
| Icosapent Ethyl | Icosapent Ethyl | 289 | 94 |
| Ezetimibe | Ezetimibe | 241 | 57 |
| Flecainide Acetate | Flecainide Acetate | 238 | 39 |
| Digoxin | Digoxin | 230 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 44 |
| Famotidine | Famotidine | 204 | 45 |
| Creon | Lipase/Protease/Amylase | 199 | 39 |
| Linzess | Linaclotide | 199 | 37 |
| Cilostazol | Cilostazol | 196 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 194 | 43 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 188 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 181 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 34 |
| Azelastine Hcl | Azelastine Hcl | 174 | 45 |
| Dexlansoprazole Dr | Dexlansoprazole | 168 | 32 |
| Azithromycin | Azithromycin | 166 | 134 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 40 |
| Finasteride | Finasteride | 151 | 34 |
| Labetalol Hcl | Labetalol Hcl | 146 | 23 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 145 | 32 |
| Farxiga | Dapagliflozin Propanediol | 140 | 33 |
| Meloxicam | Meloxicam | 134 | 34 |
| Nexium | Esomeprazole Magnesium | 130 | 17 |
| Nexletol | Bempedoic Acid | 127 | 17 |
| Mupirocin | Mupirocin | 123 | 41 |
| Propranolol Hcl | Propranolol Hcl | 123 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 122 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 32 |
| Mometasone Furoate | Mometasone Furoate | 114 | 25 |
| Lisinopril | Lisinopril | 111 | 25 |
| Repatha Sureclick | Evolocumab | 103 | 20 |
| Clobetasol Propionate | Clobetasol Propionate | 100 | 24 |
| Verquvo | Vericiguat | 98 | 13 |
| Multaq | Dronedarone Hcl | 91 | 16 |
| Donepezil Hcl | Donepezil Hcl | 90 | 21 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 89 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 87 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 15 |
| Allopurinol | Allopurinol | 86 | 20 |
| Nifedipine Er | Nifedipine | 86 | 18 |
| Lidocaine | Lidocaine | 85 | 17 |
| Metformin Hcl | Metformin Hcl | 83 | 22 |
| Verapamil Er | Verapamil Hcl | 83 | 11 |
| Procto-Med Hc | Hydrocortisone | 80 | 16 |
| Praluent Pen | Alirocumab | 79 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 73 | suppressed |
| Restasis | Cyclosporine | 73 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 72 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 42 |
| Bepotastine Besilate | Bepotastine Besilate | 70 | 15 |
| Midodrine Hcl | Midodrine Hcl | 70 | 12 |
| Fluocinonide | Fluocinonide | 68 | 13 |
| Potassium Chloride | Potassium Chloride | 68 | 16 |
| Halobetasol Propionate | Halobetasol Propionate | 65 | 21 |
| Alendronate Sodium | Alendronate Sodium | 64 | suppressed |
| Telmisartan | Telmisartan | 64 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 62 | 11 |
| Ozempic | Semaglutide | 62 | suppressed |
| Eplerenone | Eplerenone | 60 | 11 |
| Torsemide | Torsemide | 60 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 18 |
| Hydrocortisone | Hydrocortisone | 54 | 12 |
| Folic Acid | Folic Acid | 51 | 14 |
| Trazodone Hcl | Trazodone Hcl | 51 | 20 |
| Ketoconazole | Ketoconazole | 50 | 13 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 46 | 11 |
| Colchicine | Colchicine | 45 | 11 |
| Irbesartan | Irbesartan | 45 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 11 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 44 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 42 | suppressed |
| Bystolic | Nebivolol Hcl | 42 | suppressed |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 42 | 12 |
| Sotalol | Sotalol Hcl | 41 | suppressed |
| Clotrimazole | Clotrimazole | 40 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 14 |
| Propafenone Hcl | Propafenone Hcl | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 31 | suppressed |
| Edarbi | Azilsartan Medoxomil | 31 | suppressed |
| Prednisone | Prednisone | 30 | 16 |
| Amoxicillin | Amoxicillin | 29 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Livalo | Pitavastatin Calcium | 29 | suppressed |
| Metolazone | Metolazone | 28 | 17 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Benicar | Olmesartan Medoxomil | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin Calcium | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Plavix | Clopidogrel Bisulfate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Corlanor | Ivabradine Hcl | 15 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Licart | Diclofenac Epolamine | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Proctozone-Hc | Hydrocortisone | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Camzyos | Mavacamten | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Hydrocortisone Valerate | Hydrocortisone Valerate | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,416.35 · 100 records | Boston Scientific Corporation | ABRYSVO, AVEIR, AVVIGO Guidance System, CAMZYOS, CAPVAXIVE, COMIRNATY, Cleerly Ischemia, Cleerly Labs, ELIQUIS, FARAPULSE, FARXIGA, FUROSCIX, Flector, General - Therapies, JARDIANCE, LEQVIO, LODOCO, LUX-Dx Insertable Cardiac Monitor, Licart, NURTEC ODT, PREVNAR 20, REPATHA, Tirosint, VERQUVO, Venclose Maven Catheter, WATCHMAN, WATCHMAN Access System, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error